Financing Influenza Vaccine R&D

Size: px
Start display at page:

Download "Financing Influenza Vaccine R&D"

Transcription

1 Financing Influenza Vaccine R&D WHO GAP-II Geneve, Switzerland July 13, 2011 Robin Robinson, Ph.D. Deputy Assistant Secretary & Director HHS/ASPR/BARDA 0

2 Vaccine Development is Risky, Lengthy, & Expensive PHASES PRODUCT PIPELINE Preclinical Development IND Discovery Phase I Phase II Phase III Licensure NIH NIH ($11.8B) Valley of Death BARDA ARD BARDA ($540M) BLA Production & Delivery Project BARDA BioShield ($5.6B) Licensed Product 1-3% 5-17% 10-25% 18-35% 45-70% 90% PROBABILITY OF SUCCESS TO LICENSURE TIME PIPELINE PHASE COST 3-7 yr yr 1-2 yr yr yr 1-2 yrs $100M -130M $60-70M $70M-100M $130M-160M $190M-220M $18M-20M 1

3 Pre-2003 Pandemic Influenza Vaccine Goal & Strategy Egg-based Vaccines Demand for Healthcare Services weeks Increase Supplies of Critical Materiel Current Healthcare Capacity 2

4 Pre-2004 Targets for Influenza Vaccine R&D Funding Basic research: virology, immunology & epidemiology Product R & D Virus strains Vaccine discovery Vaccine early development Vaccine advanced development Vaccine post-licensure Surveillance: virus strain, disease burden, & vaccine effectiveness Vaccine AE monitoring

5 Influenza Vaccine R&D Funding: Age of Public Private Partnerships Vaccine Industry Governments: Intramural & Extramural Academia Non-Government & Philanthropic Organizations Venture Capital

6 Pre-2004 Influenza Vaccine R&D Funding Sources $100 s M Govt. Funding Primarily for Basic Research & Early Vaccine Development through Annual Appropriations 5

7 U.S. Pandemic Influenza Strategic Plan (2005) Establish domestic production capacity and stockpiles of countermeasures to ensure: immediate vaccination of front-line personnel and at-risk populations; and vaccination of the entire population after the emergence of a virus with pandemic potential;

8 Influenza Vaccine R&D Strategy Near-term Fortify egg-based influenza vaccine mfg. capacity Mid-term Develop antigen- and dose-sparing vaccine approaches with adjuvants Develop cell-based influenza vaccines Long-term Develop recombinant- and molecular-based influenza vaccines Develop universal influenza vaccines

9 Pandemic Influenza Vaccine Goal & Strategy Cell-based Vaccines + Adjuvants H5N1 Pre-Pandemic Vaccines Egg-based Vaccines Demand for Healthcare Services weeks Increase Supplies of Critical Materiel Current Healthcare Capacity 8

10 Targets for Influenza Vaccine R&D Funding Basic research: virology, immunology & epidemiology Product R & D Virus strains Vaccine discovery Vaccine early development Vaccine advanced development Vaccine post-licensure Surveillance: virus strain, disease burden, & vaccine effectiveness Vaccine manufacturing: mfg. process, lot release assays, & stockpiling Vaccine distribution Vaccine administration Vaccine AE monitoring

11 Pre-H1N1 Pandemic Influenza Vaccine R&D Funding Sources $100 s M $10 s B USG Funding through Annual (Basic Research & Early Development) & Supplemental Appropriations (Advanced Development. Mfg. & Stockpiling) 10

12 Influenza Vaccine R&D Funding: Post-2009 Challenges Pandemic vaccination realities Post-pandemic fatigue among senior leaders in all sectors Budget austerity in governments Economic pressures in industry from stockholders for reliable opportunities & faster ROI Venture capital investments in biotech are drying up

13 Post Pandemic Influenza Vaccine Goal & Strategy Egg- & Cellbased Vaccines + Adjuvants Pre-Pandemic Vaccines Recombinant Vaccines Demand for Healthcare Services weeks weeks Increase Supplies of Critical Materiel Current Healthcare Capacity 12

14 Changing Tides for Influenza Vaccine R&D Funding Sources $100 s M $10 s B $1 s B 13

15 Influenza Vaccine R&D Funding: Possible Solutions Sets Near-term Nurture Public Private Partnerships with more cooperative agreements in light of static funding (e.g., use Govt.-sponsored core services) Shorten influenza vaccine manufacturing timeline Utilize multi-purpose product technologies Complete studies for cell-based vaccines towards licensure Complete studies for vaccines with adjuvants towards licensure for pandemic & some seasonal usages in special populations Support multi-product, flexible mfg. facilities Mid-term Support vaccine distribution & administration R&D Continue support of recombinant- & molecular-based vaccines Support vaccine R&D from end-to-end (discovery administration) Long-term Continue support for universal influenza vaccine development

U.S. Readiness for Pandemics

U.S. Readiness for Pandemics 0 U.S. Readiness for Pandemics 5 th National Emergency Management Summit Brooklyn, NY September 15, 2011 Robin Robinson, Ph.D. Deputy Assistant Secretary for Preparedness & Response (HHS/ASPR) Director

More information

PROMOTING AN EFFECTIVE MEDICAL COUNTERMEASURES ENTERPRISE

PROMOTING AN EFFECTIVE MEDICAL COUNTERMEASURES ENTERPRISE PROMOTING AN EFFECTIVE MEDICAL COUNTERMEASURES ENTERPRISE Gerald R. Kovacs, PhD Director, Division of Chem/Bio/Rad/Nuc Medical Countermeasures Biomedical Advanced Research and Development Authority Assistant

More information

OPPORTUNITIES FOR HHS & DOD COLLABORATION FOR MEDICAL COUNTERMEASURES

OPPORTUNITIES FOR HHS & DOD COLLABORATION FOR MEDICAL COUNTERMEASURES OPPORTUNITIES FOR HHS & DOD COLLABORATION FOR MEDICAL COUNTERMEASURES Dr. Robert P. Kadlec Assistant Secretary for Preparedness and Response U.S. Department of Health and Human Services 2017 Chemical and

More information

Successful Collaboration and Preparedness in Global Governance

Successful Collaboration and Preparedness in Global Governance United States Department of Health & Human Services Office of the Assistant Secretary for Preparedness and Response Successful Collaboration and Preparedness in Global Governance ISARIC meeting London,

More information

Approaches to Pandemic Influenza Vaccine Preparedness

Approaches to Pandemic Influenza Vaccine Preparedness United States Department of Health & Human Services Office of the Assistant Secretary for Preparedness and Response Approaches to Pandemic Influenza Vaccine Preparedness Julie Schafer, MPH, MS Influenza

More information

Industry Perspective: Strategies and costs associated with increasing seasonal influenza vaccine. since 2006

Industry Perspective: Strategies and costs associated with increasing seasonal influenza vaccine. since 2006 Industry Perspective: Strategies and costs associated with increasing seasonal influenza vaccine use from high to low income countries since 2006 Dr. Michael Watson, sanofi-pasteur on behalf of WHO GAP

More information

Understanding vaccine development

Understanding vaccine development Understanding vaccine development Firdausi Qadri Director, Centre for Vaccine Sciences International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b) Outline of this talk 1. Understanding disease

More information

Product Development for Public Health & Emerging Infections

Product Development for Public Health & Emerging Infections Product Development for Public Health & Emerging Infections Michael G Kurilla, MD-PhD Director, Office of BioDefense Research Affairs Division of Microbiology & Infectious Diseases Associate Director,

More information

Alternative models for influenza vaccine R&D financing

Alternative models for influenza vaccine R&D financing Alternative models for influenza vaccine R&D financing Third WHO consultation on Global Action Plan on Influenza Vaccines (GAPIII) Nov 15-16 2016 John-Arne Røttingen, interim CEO of CEPI Influenza the

More information

Stockpiling of H5N1 vaccines

Stockpiling of H5N1 vaccines Stockpiling of H5N1 vaccines Norbert W. Hehme EVM Influenza Pandemic Working Group EU-Commission Workshop on Stockpiling of Medicinal Products February 21/22, 2008 European Vaccine Manufacturers 1 (EVM)

More information

Vaccine Innovation and Adult Immunization Landscape

Vaccine Innovation and Adult Immunization Landscape Vaccine Innovation and Adult Immunization Landscape National Adult and Influenza Immunization Summit, May 12-14, 2015 Phyllis Arthur Senior Director Vaccines, Immunotherapeutics & Diagnostics Policy parthur@bio.org

More information

Application of Single-Use Technologies in Medical Countermeasure Development & Manufacturing for Emerging Pathogens

Application of Single-Use Technologies in Medical Countermeasure Development & Manufacturing for Emerging Pathogens Application of Single-Use Technologies in Medical Countermeasure Development & Manufacturing for Emerging Pathogens BPSA s 7 th Annual Int l Single-Use Summit July 13, 2017 Mike Angelastro Director (acting),

More information

Towards a Sustainable Global Infrastructure for Medical Countermeasures

Towards a Sustainable Global Infrastructure for Medical Countermeasures Towards a Sustainable Global Infrastructure for Medical Countermeasures Institute of Medicine The Public Health Emergency Medical Countermeasures Enterprise: Innovative Strategies to Enhance Products from

More information

Global Pandemic Preparedness Research Efforts. Klaus Stöhr. WHO Global Influenza Programme. Today

Global Pandemic Preparedness Research Efforts. Klaus Stöhr. WHO Global Influenza Programme. Today Global Pandemic Preparedness Research Efforts Klaus Stöhr 3 Today Medium-term applied research linked to medical and public health interventions addressing the current pandemic situation in Asia Natural

More information

Michel BAIJOT Vice President, WW Business Development & Strategic Alliances

Michel BAIJOT Vice President, WW Business Development & Strategic Alliances Technology Transfer and Vaccines: The GSK Experience WHO Workshop on Technology Transfer for Local Manufacturing Capacity of Vaccines Geneva, November 30th, 2010 Michel BAIJOT Vice President, WW Business

More information

GSK s Candidate Influenza A (H5N1) Virus Monovalent Vaccine

GSK s Candidate Influenza A (H5N1) Virus Monovalent Vaccine GSK s Candidate Influenza A (H5N1) Virus Monovalent Vaccine Regulatory Pathway for Licensure VRBPAC, February 29, 2012 Katalin Abraham, Director, US Regulatory Affairs GSK Biologicals GSK s Influenza Vaccines

More information

7th Mena Influenza Stakeholders Meeting. WHO Influenza Strategy Development and Vaccine-related Research Priorities

7th Mena Influenza Stakeholders Meeting. WHO Influenza Strategy Development and Vaccine-related Research Priorities 7th Mena Influenza Stakeholders Meeting WHO Influenza Strategy Development and Vaccine-related Research Priorities Wenqing Zhang 9 10 September 2017 Riga, Latvia 1 Seasonal influenza 1 billion cases yearly

More information

GSK commitment to influenza prevention

GSK commitment to influenza prevention GSK commitment to influenza prevention Dr Catia Ferreira Influenza Portfolio US Medical Affairs Leader GSK Vaccines GSK commitment to Influenza Rixensart (Belgium) Shenzhen (China) Marietta (US) Saint-Amand

More information

WHO GLOBAL ACTION PLAN FOR INFLUENZA VACCINES

WHO GLOBAL ACTION PLAN FOR INFLUENZA VACCINES WHO GLOBAL ACTION PLAN FOR INFLUENZA VACCINES SURVEY QUESTIONNAIRE A.1. Introduction The Global Action Plan for Influenza Vaccines (GAP) was launched in 2006 as a ten year initiative to address the anticipated

More information

Pandemic Influenza Preparedness and Response

Pandemic Influenza Preparedness and Response Pandemic Influenza Preparedness and Response US Department of Health and Human Services Bruce Gellin, MD, MPH Director, National Vaccine Program Office The pandemic influenza clock is ticking. We just

More information

An Affordable Pandemic Influenza Vaccine Solution for Developing Countries (and Developed Countries Too)

An Affordable Pandemic Influenza Vaccine Solution for Developing Countries (and Developed Countries Too) An Affordable Pandemic Influenza Vaccine Solution for Developing Countries (and Developed Countries Too) James M. Robinson, PE VP Technical and Quality Operations Novavax, Inc. New Cells for New Vaccines

More information

TESTIMONY OF PHYLLIS ARTHUR, SENIOR DIRECTOR FOR VACCINES, IMMUNOTHERAPEUTICS AND DIAGNOSTICS POLICY, BIOTECHNOLOGY INDUSTRY ORGANIZATION (BIO)

TESTIMONY OF PHYLLIS ARTHUR, SENIOR DIRECTOR FOR VACCINES, IMMUNOTHERAPEUTICS AND DIAGNOSTICS POLICY, BIOTECHNOLOGY INDUSTRY ORGANIZATION (BIO) TESTIMONY OF PHYLLIS ARTHUR, SENIOR DIRECTOR FOR VACCINES, IMMUNOTHERAPEUTICS AND DIAGNOSTICS POLICY, BIOTECHNOLOGY INDUSTRY ORGANIZATION (BIO) SENATE HELP COMMITTEE May 17, 2011 Good morning Chairman

More information

The Inclusion of Seasonal Influenza Viruses and Genetic Sequence Data (GSD) in the Context of the Pandemic Influenza Preparedness (PIP) Framework

The Inclusion of Seasonal Influenza Viruses and Genetic Sequence Data (GSD) in the Context of the Pandemic Influenza Preparedness (PIP) Framework The Inclusion of Seasonal Influenza Viruses and Genetic Sequence Data (GSD) in the Context of the Pandemic Influenza Preparedness (PIP) Framework A position paper from the Directors of the GISRS WHO Collaborating

More information

Human H5N1 and Pandemic Vaccines Practicalities of Production: A perspective from Industry

Human H5N1 and Pandemic Vaccines Practicalities of Production: A perspective from Industry Human H5N1 and Pandemic Vaccines Practicalities of Production: A perspective from Industry Luc Hessel M.D. Pandemic Influenza Working Group European Vaccine Manufacturers 4th Joint EC/ECDC/WHO Workshop

More information

Advancements in CBRN Medical Countermeasures

Advancements in CBRN Medical Countermeasures Advancements in CBRN Medical Countermeasures Gerald R. Kovacs, Ph.D. Division of CBRN Countermeasures Biomedical Advanced Research and Development Authority Presentation at the MARCE Public Health Emergency

More information

BARDA s Division of Chemical, Biological, Radiological and Nuclear Medical Countermeasures

BARDA s Division of Chemical, Biological, Radiological and Nuclear Medical Countermeasures BARDA s Division of Chemical, Biological, Radiological and Nuclear Medical Countermeasures Joe Larsen, Ph.D. Director (Acting) BARDA Division of CBRN Medical Countermeasures January 2018 ASPR: Saving Lives

More information

Conversation with Tom Inglesby on October 2, 2013

Conversation with Tom Inglesby on October 2, 2013 Participants Conversation with Tom Inglesby on October 2, 2013 Tom Inglesby, M.D., Chief Executive Officer and Director, University of Pittsburgh Medical Center (UPMC) Center for Health Security Alexander

More information

Page 1 of 5 For Immediate Release Office of the Press Secretary July 17, 2007 Fact Sheet: Implementation of the National Strategy for Pandemic Influenza A One-Year Summary Of Efforts To Better Protect

More information

On behalf of the Infectious Diseases Society of America (IDSA), I am pleased to provide

On behalf of the Infectious Diseases Society of America (IDSA), I am pleased to provide Transmitted by Jonathan Nurse, Director of Government Relations, IDSA The Infectious Diseases Society of America s (IDSA) Fiscal Year 2015 Funding Statement Submitted to the House Appropriations Subcommittee

More information

Public Safety and Health Cooperation from the Canadian Perspective

Public Safety and Health Cooperation from the Canadian Perspective 1 2 Public Safety and Health Cooperation from the Canadian Perspective Presentation by: Dr. Rainer Engelhardt Assistant Deputy Minister Infectious Disease Prevention and Control Public Health Agency of

More information

2009-H1N1 Pandemic Influenza: DHS Perspective

2009-H1N1 Pandemic Influenza: DHS Perspective 2009-H1N1 Pandemic Influenza: DHS Perspective Terry Adirim, MD, MPH Senior Advisor for Science and Public Health Office of Health Affairs U.S. Department of Homeland Security The National Emergency Management

More information

PANDEMIC INFLUENZA PREPAREDNESS: STATE CHALLENGES

PANDEMIC INFLUENZA PREPAREDNESS: STATE CHALLENGES PANDEMIC INFLUENZA PREPAREDNESS: STATE CHALLENGES A Presentation to the Council of State Governments Health Policy Forum by Jeffrey Levi, Ph.D., Executive Director Trust for America s Health June 23, 2006

More information

President's FY 2009 Budget Request for R&D and Public Health Programs

President's FY 2009 Budget Request for R&D and Public Health Programs Request for R&D and Public Health Programs (in millions) : http://www.whitehouse.gov/omb/budget/fy2007/ FY Final Appropriations: http://thomas.loc.gov/home/approp/app08.html FY Levels based on Documents

More information

Request for Letters of Intent. International Development of H5N1 Influenza Vaccines

Request for Letters of Intent. International Development of H5N1 Influenza Vaccines Request for Letters of Intent International Development of H5N1 Influenza Vaccines The World Health Organization (WHO) intends to provide funding to developing (1) country vaccine manufacturers to develop

More information

Pandemic Preparedness: Pigs, Poultry, and People versus Plans, Products, and Practice

Pandemic Preparedness: Pigs, Poultry, and People versus Plans, Products, and Practice SUPPLEMENT ARTICLE Pandemic Preparedness: Pigs, Poultry, and People versus Plans, Products, and Practice Julie L. Gerberding Centers for Disease Control and Prevention, Atlanta, Georgia Influenza pandemic

More information

The Crisis in. Vaccine Development

The Crisis in. Vaccine Development The Crisis in Vaccine Development Stanley A. Plotkin 1 Annecy 2015 The Evolution of the Vaccine Industry 1. 18 th -19 th Centuries Pioneers 2. 1900-1950 National Producers 3. 1960-1980 Globalization 4.

More information

PIP Framework Information Session 10 April 2018

PIP Framework Information Session 10 April 2018 Pandemic Influenza Preparedness Framework Sharing of influenza viruses & access to vaccines and other benefits PIP Framework Information Session 10 April 2018 PIP Framework Information Session Purpose:

More information

VICAL INC FORM 8-K. (Current report filing) Filed 11/02/06 for the Period Ending 11/02/06

VICAL INC FORM 8-K. (Current report filing) Filed 11/02/06 for the Period Ending 11/02/06 VICAL INC FORM 8-K (Current report filing) Filed 11/02/06 for the Period Ending 11/02/06 Address 10390 PACIFIC CENTER COURT. SAN DIEGO, CA 92121-4340 Telephone 858-646-1100 CIK 0000819050 Symbol VICL SIC

More information

DRAFT PANDEMIC INFLUENZA PREPAREDNESS AND RESPONSE PLAN. Department of Health and Human Services. Core Document August 2004

DRAFT PANDEMIC INFLUENZA PREPAREDNESS AND RESPONSE PLAN. Department of Health and Human Services. Core Document August 2004 DRAFT PANDEMIC INFLUENZA PREPAREDNESS AND RESPONSE PLAN Department of Health and Human Services Core Document August 2004 Comments on this draft plan should be forwarded to: National Vaccine Program Office

More information

New Delhi International Ministerial Conference on Avian and Pandemic Influenza Dec 4-6th, 2007

New Delhi International Ministerial Conference on Avian and Pandemic Influenza Dec 4-6th, 2007 New Delhi International Ministerial Conference on Avian and Pandemic Influenza Dec 4-6th, 2007 Session IV Influenza Pandemic Preparedness Dr Paul R Gully Health Security and Environment, Geneva Avian Influenza

More information

Preparedness 101: Promotion, Funding, and the Future

Preparedness 101: Promotion, Funding, and the Future Preparedness 101: Promotion, Funding, and the Future Joanne D. Andreadis, PhD Senior Advisor for Laboratory Preparedness Office of Public Health Preparedness and Response May 22, 2012 Centers for Disease

More information

H1N1 Planning, Response and Lessons to Date

H1N1 Planning, Response and Lessons to Date H1N1 Planning, Response and Lessons to Date Glen Nowak, Ph.D. Acting Director Division of News and Electronic Media Centers for Disease Control and Prevention The Beginning Mid-April indications that we

More information

Update on A(H1N1) pandemic and seasonal vaccine availability. July 7, 2009

Update on A(H1N1) pandemic and seasonal vaccine availability. July 7, 2009 Update on A(H1N1) pandemic and seasonal vaccine availability July 7, 2009 Presentation objectives and approach Presentation Objectives Review production status for 2009-2010 Northern Hemisphere vaccine

More information

FINAL RECOMMENDATIONS ON PANDEMIC INFLUENZA

FINAL RECOMMENDATIONS ON PANDEMIC INFLUENZA Comprehensive Family Immunization Family and Community Health Area FINAL RECOMMENDATIONS ON PANDEMIC INFLUENZA TECHNICAL ADVISORY GROUP ON VACCINE-PREVENTABLE DISEASES 24-26 AUGUST 2009, COSTA RICA Epidemiological

More information

Medicago: transforming the approach to vaccines and protein-based therapeutics. Bruce D. Clark PhD President & CEO September 27, 2017

Medicago: transforming the approach to vaccines and protein-based therapeutics. Bruce D. Clark PhD President & CEO September 27, 2017 Medicago: transforming the approach to vaccines and protein-based therapeutics Bruce D. Clark PhD President & CEO September 27, 2017 Medicago Overview Focus Manufacturing technology Vaccine technology

More information

Advancing Pandemic Preparedness through APSED III

Advancing Pandemic Preparedness through APSED III Advancing Pandemic Preparedness through APSED III Masaya Kato Programme Area Manager Country Health Emergency Preparedness and the IHR (CPI) WHO Health Emergencies Programme (WHE) WHO Western Pacific Regional

More information

Vaccinating Against the Pandemic H1N1 Influenza Virus. Background. Milestones in Influenza Vaccine Development. Increased Safety, Less Reactogenicity

Vaccinating Against the Pandemic H1N1 Influenza Virus. Background. Milestones in Influenza Vaccine Development. Increased Safety, Less Reactogenicity Vaccinating Against the Pandemic H1N1 Influenza Virus Background Alvin Nelson El Amin, MD, MPH Medical Director Immunization Program Milestones in Influenza Vaccine Development Isolation of the influenza

More information

Appendix 3: Federal Government Agencies Involved in Immunization

Appendix 3: Federal Government Agencies Involved in Immunization Appendix 3: Federal Government Agencies Involved in Immunization Department of Health and Human Services (HHS) Secretary of Health and Human Services Directs all HHS activities. Office of the Assistant

More information

Feasibility of Production of Human AI Vaccine in AI vaccine Manufacturers in China. Gu Hong Ministry of Agriculture of P. R. China

Feasibility of Production of Human AI Vaccine in AI vaccine Manufacturers in China. Gu Hong Ministry of Agriculture of P. R. China Feasibility of Production of Human AI Vaccine in AI vaccine Manufacturers in China Gu Hong Ministry of Agriculture of P. R. China AI -- common challenge to the all countries Global cooperation in control

More information

WORLD BANK RESPONSE TO INFLUENZA A(H1N1) Rakesh Nangia Director, Strategy & Operations Human Development Network

WORLD BANK RESPONSE TO INFLUENZA A(H1N1) Rakesh Nangia Director, Strategy & Operations Human Development Network WORLD BANK RESPONSE TO INFLUENZA A(H1N1) Rakesh Nangia Director, Strategy & Operations Human Development Network Tokyo, July 2009 World Bank Response to A(H1N1) Influenza A(H1N1) Global Health and Risks

More information

Influenza Vaccine Innovation

Influenza Vaccine Innovation United States Department of Health & Human Services Office of the Assistant Secretary for Preparedness and Response Influenza Vaccine Innovation New Vaccines Approved and on the Way Rick A. Bright, Ph.D.

More information

Centers for Disease Control and Prevention (CDC) FY 2009 Budget Request Summary

Centers for Disease Control and Prevention (CDC) FY 2009 Budget Request Summary Centers for Disease Control and Prevention (CDC) FY 2009 Budget Request Summary The President s FY 2009 Budget Request for the Centers for Disease Control and Prevention (CDC) discretionary funding is

More information

TB Vaccine Development Strategy Overview

TB Vaccine Development Strategy Overview TB Vaccine Development Strategy Overview October 28, 2014 Angeline Nanni, MBA, MS Aeras Director, Global Access TB is Mother Nature s number one killer over the past centuries TB is spread through the

More information

BioDiem to present at Hong Kong biotech investment forum

BioDiem to present at Hong Kong biotech investment forum ASX Announcement BIODIEM LTD ABN 20 096 845 993 Suite 3, Level 11, 470 Collins Street, Melbourne, Victoria, 3000 Australia Phone: +613 9613 4100 Web: www.biodiem.com BioDiem to present at Hong Kong biotech

More information

The Impact of Pandemic Influenza on Public Health

The Impact of Pandemic Influenza on Public Health This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike License. Your use of this material constitutes acceptance of that license and the conditions of use of materials on this

More information

Influenza. Influenza vaccines (WHO position paper) Weekly Epid. Record (2005, 80: ) 287

Influenza. Influenza vaccines (WHO position paper) Weekly Epid. Record (2005, 80: ) 287 Program Management 82_19 SAGE encouraged all countries to consider their preparedness for a potential influenza pandemic, recognizing that it would occur before strain-specific vaccine can be made in significant

More information

Intercell and Novartis form world leading strategic partnership to drive vaccines innovation

Intercell and Novartis form world leading strategic partnership to drive vaccines innovation Intercell and Novartis form world leading strategic partnership to drive vaccines innovation Alliance creates opportunity for two strong innovators to combine development efforts in attractive areas Intercell

More information

Pandemic Influenza (H1N1) 2009 Lessons Learned: Thailand Department of Disease Control Ministry of Public Health 11 March 2010

Pandemic Influenza (H1N1) 2009 Lessons Learned: Thailand Department of Disease Control Ministry of Public Health 11 March 2010 Pandemic Influenza (H1N1) 2009 Lessons Learned: Thailand Department of Disease Control Ministry of Public Health 11 March 2010 Presented by: Dr. Ajchara Vararuk SCOPE 1. National policy. 2. Mass Gatherings

More information

DCVMN Perspective: Barriers and how developing countries manufacturers will be able to reach goal.

DCVMN Perspective: Barriers and how developing countries manufacturers will be able to reach goal. DCVMN Perspective: Barriers and how developing countries manufacturers will be able to reach goal. Dr. Suresh Jadhav Executive Director Serum Institute of India Limited. ssj@seruminstitute.com H1N1 Pandemic:

More information

BARDA INFLUENZA PROGRAM OVERVIEW

BARDA INFLUENZA PROGRAM OVERVIEW BARDA INFLUENZA PROGRAM OVERVIEW Drs. Armen Donabedian and Michael Wathen Vaccines and Therapeutics Resilient People. Healthy Communities. A Nation Prepared. 0 BARDA Overview 1 Perpetual challenge of responding

More information

EC research and innovation strategy and actions

EC research and innovation strategy and actions EC research and innovation strategy and actions for preparedness and response to outbreaks IMI Stakeholder Forum 28-29 September 2016 Line Matthiessen Head of Unit E.3 Health Directorate DG Research &

More information

Technology Transfer from the Perspective of IFPMA vaccine members

Technology Transfer from the Perspective of IFPMA vaccine members Technology Transfer from the Perspective of IFPMA vaccine members WHO Workshop on Technology Transfer for Local Manufacturing Capacity of Vaccines Michael Watson (Sanofi Pasteur) Chair of IFPMA Biologicals

More information

Pandemic Influenza Preparedness Framework. Sharing influenza viruses & access to vaccines and other benefits

Pandemic Influenza Preparedness Framework. Sharing influenza viruses & access to vaccines and other benefits Pandemic Influenza Preparedness Framework Sharing influenza viruses & access to vaccines and other benefits What is PIP? Landmark, innovative public health arrangement to increase global preparedness to

More information

Development of Recombinant MERS-CoV Spike (S) Nanoparticle Vaccine

Development of Recombinant MERS-CoV Spike (S) Nanoparticle Vaccine Development of Recombinant MERS-CoV Spike (S) Nanoparticle Vaccine Russell P. Wilson Senior Vice President, Business Development Vaccine World MENA & CIS 2014 Istanbul, Turkey November 19, 2014 1 www.novavax.com

More information

Being Ready for the Next Pandemic: Expanded Access to Pandemic Vaccines

Being Ready for the Next Pandemic: Expanded Access to Pandemic Vaccines Being Ready for the Next Pandemic: Expanded Access to Pandemic Vaccines Coordination Between Public Health and Pharmacies Sam Graitcer, MD Immunization Services Division, NCIRD CDC Pandemic Influenza Vaccine

More information

Thailand s avian influenza control and pandemic influenza preparedness. Supamit Chunsuttiwat Ministry of Public Health 12 July 2006

Thailand s avian influenza control and pandemic influenza preparedness. Supamit Chunsuttiwat Ministry of Public Health 12 July 2006 Thailand s avian influenza control and pandemic influenza preparedness Supamit Chunsuttiwat Ministry of Public Health 12 July 2006 Avian influenza situation 2004-05 Human cases Poultry outbreaks 250 200

More information

USDA APHIS One Health Initiative

USDA APHIS One Health Initiative Biorisk Management in a One Health World USDA APHIS One Health Initiative Joseph F. Annelli, DVM, MS One Health Coordination Center U.S. Department of Agriculture Animal and Plant Health Inspection Service

More information

USG Policy Perspectives on Global Influenza

USG Policy Perspectives on Global Influenza USG Policy Perspectives on Global Influenza IOM Committee for the Assessment of DoD-GEIS Influenza Surveillance & Response Programs Ms. Ellen P. Embrey Deputy Assistant Secretary of Defense Force Health

More information

MEDICAL AND PUBLIC HEALTH PREPAREDNESS AND RESPONSE: ARE WE READY FOR FUTURE THREATS?

MEDICAL AND PUBLIC HEALTH PREPAREDNESS AND RESPONSE: ARE WE READY FOR FUTURE THREATS? FEBRUARY 26, 2015 MEDICAL AND PUBLIC HEALTH PREPAREDNESS AND RESPONSE: ARE WE READY FOR FUTURE THREATS? U.S. SENATE COMMITTEE ON HEALTH, EDUCATION, LABOR, AND PENSIONS ONE HUNDRED FOURTEENTH CONGRESS,

More information

Planning for Pandemic Influenza in York County: Considerations for Healthcare and Medical Response

Planning for Pandemic Influenza in York County: Considerations for Healthcare and Medical Response Planning for Pandemic Influenza in York County: Considerations for Healthcare and Medical Response York County Pandemic Influenza Stakeholders Village by the Sea, Wells, Maine 8 August 2006 Steven J Trockman,

More information

Emergency Use Authorizations

Emergency Use Authorizations Emergency Use Authorizations May 26, 2016 Quality Improvement Forum Call Celia Hagan, MPH Senior Specialist, Public Policy Overview Emergency Use Authorization (EUA) authority EUA issuance process Zika

More information

On behalf of the Infectious Diseases Society of America (IDSA), I offer testimony in

On behalf of the Infectious Diseases Society of America (IDSA), I offer testimony in Testimony of the Infectious Diseases Society of America (IDSA) on the Fiscal Year 2018 Department of Health and Human Services Budget Prepared for the U.S. House of Representatives Subcommittee on Labor-HHS-Education

More information

CPRIT Overview. Cancer Centers Administrators Forum April 4, 2016

CPRIT Overview. Cancer Centers Administrators Forum April 4, 2016 CPRIT Overview Cancer Centers Administrators Forum April 4, 2016 CPRIT s Unique Role in the Fight Against Cancer Overview: Created by the Texas Legislature and citizens in 2007 $3 billion over 10 years

More information

FDA Approved Recombinant Hemagglutinin Influenza Vaccine Protects Against Drift Influenza Viruses

FDA Approved Recombinant Hemagglutinin Influenza Vaccine Protects Against Drift Influenza Viruses FDA Approved Recombinant Hemagglutinin Influenza Vaccine Protects Against Drift Influenza Viruses 2 nd International conference on Flu October 31- November 02, 2016 San Francisco, California, USA Protein

More information

Aviragen Therapeutics, Inc. and Vaxart Inc. Joint Conference Call UNLOCKING THE FULL POTENTIAL OF ORAL VACCINES

Aviragen Therapeutics, Inc. and Vaxart Inc. Joint Conference Call UNLOCKING THE FULL POTENTIAL OF ORAL VACCINES Aviragen Therapeutics, Inc. and Vaxart Inc. Joint Conference Call UNLOCKING THE FULL POTENTIAL OF ORAL VACCINES October 30, 2017 Safe Harbor This presentation contains forward-looking statements about

More information

Working with US and International Partners to Strengthen Preparedness & Response at the Domestic-International Interface

Working with US and International Partners to Strengthen Preparedness & Response at the Domestic-International Interface How can the U.S. efforts in international public health disaster and emergency response strengthened and who should take the lead? Working with US and International Partners to Strengthen Preparedness

More information

Preparing For Pandemic Influenza: What the CDC and HHS Recommend You Can Do

Preparing For Pandemic Influenza: What the CDC and HHS Recommend You Can Do Preparing For Pandemic Influenza: What the CDC and HHS Recommend You Can Do Based on current data and information from the Centers for Disease Control (CDC) and the U.S. Department Health and Human Services

More information

BARDA INDUSTRY DAYS 10 th Anniversary November 7-8, 2017

BARDA INDUSTRY DAYS 10 th Anniversary November 7-8, 2017 BARDA INDUSTRY DAYS 10 th Anniversary November 7-8, 2017 Below is a summary of the BARDA Industry Days Conference in D.C. November 7-8, 2017. Each year this conference is organized by the Biomedical Advanced

More information

NIAID Biodefense Research Agenda

NIAID Biodefense Research Agenda NIAID Biodefense Research Agenda Deborah G. Katz, M.S., R.N. Deputy Director Office of Biodefense Research Affairs National Institute of Allergy and Infectious Diseases Princeton University September 8,

More information

Gaps in Influenza Clinical Research. Presented by: Dr Gina Samaan Technical Officer, Indonesia Field Epidemiology Training Program

Gaps in Influenza Clinical Research. Presented by: Dr Gina Samaan Technical Officer, Indonesia Field Epidemiology Training Program Gaps in Influenza Clinical Research Presented by: Dr Gina Samaan Technical Officer, Indonesia Field Epidemiology Training Program Outline 1. Global frameworks: 2010 Research Agenda 2013 BRaVe Agenda 2.

More information

Pandemic Flu Impact in U.S.

Pandemic Flu Impact in U.S. Pandemic Flu Impact in U.S. Pandemic Flu and the Potential for U.S. Economic Recession Second worst recession since World War II -- about 5.25% decline in Gross Domestic Product (GDP); $683 billion loss

More information

H1N1 Vaccine Based on CDCs ACIP Meeting, July 29, 2009

H1N1 Vaccine Based on CDCs ACIP Meeting, July 29, 2009 August 6, 2009 H1N1 Vaccine Based on CDCs ACIP Meeting, July 29, 2009 CDC s Advisory Committee on Immunization Practices (ACIP), a panel made up of medical and public health experts, met July 29, 2009,

More information

Re: Trust for America s Health Comments on Biennial Implementation Plan for the National Health Security Strategy

Re: Trust for America s Health Comments on Biennial Implementation Plan for the National Health Security Strategy Dr. Nicole Lurie, MD, MSPH Assistant Secretary for Preparedness & Response Department of Health and Human Services Washington, DC 20201 Re: Trust for America s Health Comments on Biennial Implementation

More information

Avian Influenza A(H7N9) Overview

Avian Influenza A(H7N9) Overview Avian Influenza A(H7N9) Overview Side event organized by China and WHO 21 May 2013 1 Avian Influenza A(H7N9) Novel Coronavirus (ncov) World experiencing emergence of 2 exceptional new virus infections

More information

Center for Global Health. CDC Global Health Saving Lives Overseas, Protecting Americans at Home

Center for Global Health. CDC Global Health Saving Lives Overseas, Protecting Americans at Home Center for Global Health CDC Global Health Saving Lives Overseas, Protecting Americans at Home CDC Overview Part of the U.S. Department of Health and Human Services, CDC is the nation s leading public

More information

How to successfully get a Flu Vaccination Policy accepted and implemented? the Thai experience

How to successfully get a Flu Vaccination Policy accepted and implemented? the Thai experience How to successfully get a Flu Vaccination Policy accepted and implemented? the Thai experience WHEII, June 5 th, 2012, Intercontinental Hotel, Bali, Indonesia Dr. Suwit Wibulpolprasert Senior Advisor on

More information

Pandemic Influenza Preparedness

Pandemic Influenza Preparedness Pandemic Influenza Preparedness Of the many health threats that we are preparing for, this is the one that we know will happen. Bruce G. Gellin, MD, MPH Director, National Vaccine Program Office Department

More information

Linking Pandemic Influenza Preparedness with Bioterrorism Vaccination Planning

Linking Pandemic Influenza Preparedness with Bioterrorism Vaccination Planning Linking Pandemic Influenza Preparedness with Bioterrorism Vaccination Planning APHA Annual Meeting San Francisco, California Lara Misegades, MS Director of Infectious Disease Policy November 18, 2003 Overview

More information

The story of modern vaccines begins in 1749, when Dr. Edward Jenner observed that milkmaids exposed to cowpox later subsequently not contract

The story of modern vaccines begins in 1749, when Dr. Edward Jenner observed that milkmaids exposed to cowpox later subsequently not contract 1 The story of modern vaccines begins in 1749, when Dr. Edward Jenner observed that milkmaids exposed to cowpox later subsequently not contract smallpox. Dr. Jenner used fluids from a cow s blisters to

More information

WHO INFLUENZA VACCINE RECOMMENDATION

WHO INFLUENZA VACCINE RECOMMENDATION WHO INFLUENZA VACCINE RECOMMENDATION Strategic Advisory Group of Experts (SAGE) on Immunization SAGE Working Group on Influenza Vaccine and Immunization 1 Evidence Evaluation: Conceptual Matrix Target

More information

FY 2008 Appropriations for R&D and Public Health Programs (in millions)

FY 2008 Appropriations for R&D and Public Health Programs (in millions) FY 2008 Appropriations for R&D and Public Health Programs (in millions) AGENCY PROGRAM FY 2008 Appropriations Status: http://thomas.loc.gov/home/approp/app08.html FY 2008 : http://www.whitehouse.gov/omb/budget/fy2007/

More information

Globalization and Health The regional response

Globalization and Health The regional response Zsuzsanna Jakab Director European Centre for Disease Prevention and Control (ECDC) IBA Annual Meeting Anthrax, SARS and Bioweaponry Is Globalisation Bad for Your Health? 28 September 2005, Prague Globalization

More information

2009 H1N1 Influenza Pandemic Defense Health Board Briefing

2009 H1N1 Influenza Pandemic Defense Health Board Briefing 2009 H1N1 Influenza Pandemic Defense Health Board Briefing COL Wayne Hachey DO, MPH Director Preventive Medicine Office of Deputy Assistant Secretary of Defense for Force Health Protection & Readiness

More information

Assessment of Influenza Vaccine Production Compatibilities

Assessment of Influenza Vaccine Production Compatibilities United States Department of Health & Human Services Office of the Assistant Secretary for Preparedness and Response Assessment of Influenza Vaccine Production Compatibilities Joshua Speidel, PhD Influenza

More information

Promoting Public Health Security Addressing Avian Influenza A Viruses and Other Emerging Diseases

Promoting Public Health Security Addressing Avian Influenza A Viruses and Other Emerging Diseases Promoting Public Health Security Addressing Avian Influenza A Viruses and Other Emerging Diseases Masaya Kato, WHO Viet Nam OIE Regional Workshop on Enhancing Influenza A viruses National Surveillance

More information

The Value of Product Development Partnerships in Vaccine Innovation. Hansi J. Dean International AIDS Vaccine Initiative

The Value of Product Development Partnerships in Vaccine Innovation. Hansi J. Dean International AIDS Vaccine Initiative The Value of Product Development Partnerships in Vaccine Innovation Hansi J. Dean International AIDS Vaccine Initiative The Product Development Partnership Model A non-profit partnership of public and

More information

The Vaccine Formulation Laboratory

The Vaccine Formulation Laboratory FIFTH MEETING WITH INTERNATIONAL PARTNERS ON PROSPECTS FOR INFLUENZA VACCINE TECHNOLOGY TRANSFER TO DEVELOPING COUNTRY VACCINE MANUFACTURERS The Vaccine Formulation Laboratory Adjuvant Hub & Training Center

More information

A conversation with Michael Osterholm on July 30, 2013 about pandemics

A conversation with Michael Osterholm on July 30, 2013 about pandemics A conversation with Michael Osterholm on July 30, 2013 about pandemics Participants Michael Osterholm Director, Center for Infectious Disease Research and Policy (CIDRAP), University of Minnesota Alexander

More information

November 13, 2009 Licensure, Evaluation, and Adverse Event Monitoring of the 2009 H1N1 Influenza Vaccine By Matthew Watson and Jennifer Nuzzo

November 13, 2009 Licensure, Evaluation, and Adverse Event Monitoring of the 2009 H1N1 Influenza Vaccine By Matthew Watson and Jennifer Nuzzo www.upmc-biosecurity.org www.upmc-cbn.org November 13, 2009 Licensure, Evaluation, and Adverse Event Monitoring of the 2009 H1N1 Influenza Vaccine By Matthew Watson and Jennifer Nuzzo In response to the

More information

Managing cost considerations and access to technology for cost effective vaccine manufacture in developing countries.

Managing cost considerations and access to technology for cost effective vaccine manufacture in developing countries. Managing cost considerations and access to technology for cost effective vaccine manufacture in developing countries. Amol R. Dindokar Serum Institute of India ltd. Overview Disease Control Priorities

More information